Locations:
Search IconSearch
October 14, 2019/Cancer/News & Insight

Jame Abraham, MD, FACP, Named Chair of Hematology/Medical Oncology

Renowned breast cancer researcher and editor to lead department

650×450-Jame-Abraham

Jame Abraham, MD, FACP, is the new Chair of Hematology/Medical Oncology at Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In his new position, Dr. Abraham will recruit and develop staff, and guide the department’s focus on patient access and multidisciplinary care. He also will continue as Professor of Medicine at Cleveland Clinic Lerner College of Medicine.

Most recently, Dr. Abraham was Director of the Breast Oncology Program at Cleveland Clinic’s Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program.

“Successfully leading our Hematology/Medical Oncology Department requires a leader who excels at empathy, fosters a culture of teamwork, demonstrates emotional intelligence and believes in the vision of our institute,” says Brian Bolwell, MD, Chairman, Taussig Cancer Institute, Cleveland Clinic Cancer Center. “Dr. Abraham represents these qualities and has exhibited a passion for department and caregiver development, and elevating our national reputation.”

About Dr. Abraham

Dr. Abraham earned his medical degree from Calicut Medical College in Kerala, India. He then completed a residency at the University of Connecticut, followed by a fellowship in hematology at the National Heart, Lung, and Blood Institute and a fellowship in medical oncology at the National Cancer Institute.

He worked as Chief of Hematology/Oncology, Professor of Medicine and Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research at West Virginia University before joining Cleveland Clinic in 2013.

A national principal investigator of multiple breast cancer clinical trials, Dr. Abraham has published and presented more than 200 papers. He also is Founding Editor of The Bethesda Handbook of Clinical Oncology.

Advertisement

His national breast cancer committee and leadership activities include serving as:

  • Member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee.
  • Vice Chair of NRG Oncology’s Research Strategy Committee.
  • Member of NRG Oncology’s Breast Cancer Working Committee.
  • Vice Chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Research Review Committee.

“I look forward to building upon Cleveland Clinic Taussig Cancer Institute’s position as a leader in hematology and medical oncology, delivering outstanding, compassionate patient care and innovative research,” says Dr. Abraham. “I am honored to serve patients who choose Cleveland Clinic for advanced cancer treatment and to support the department’s committed and passionate caregivers.”

Advertisement

Related Articles

Hospice nurse with patient
March 10, 2026/Cancer/News & Insight

Centering End-of-Life Care Around What Matters Most

Goal-of-care discussions drive earlier hospice access

Dr. Lauren Kopicky headshot
March 4, 2026/Cancer/Podcast

Rethinking Axillary Management in Breast Cancer (Podcast)

Clinical trials and de-escalation strategies

Lobular breast cancer cells
February 26, 2026/Cancer/News & Insight

Standard of Care for Hormone-Sensitive Advanced Breast Cancer Also Effective for Lobular Subgroup

Combination therapy improves outcomes, but lobular patients still do worse overall than ductal counterparts

Person hugging in support group
February 25, 2026/Cancer/Patient Support

Treating Substance Use Disorder in Patients with Cancer

Bringing empathy and evidence-based practice to addiction medicine

Drs. Turk and Khatri headshots
February 23, 2026/Cancer/Podcast

Beyond Mammography (Podcast)

Supplemental screening for dense breasts

Dr. Elvin Zan headshot
February 17, 2026/Cancer/Podcast

Expanding Cancer Treatment with Theranostics (Podcast)

Combining advanced imaging with targeted therapy in prostate cancer and neuroendocrine tumors

Man touching lymph nodes
February 12, 2026/Cancer/News & Insight

EGFR-MET Bispecific Antibody Shows Promise for Metastatic Head & Neck Cancer

Early results show strong clinical benefit rates

Bispecific antibodies
February 10, 2026/Cancer/Blood Cancers

MajesTEC-3 Trial Outcomes May Change Course of Myeloma Treatment

The shifting role of cell therapy and steroids in the relapsed/refractory setting

Ad